News

In patients with high C-reactive protein levels treated with NP001, investigators observed a 64% slower rate of decline in forced vital capacity.

ARIA-inducing monoclonal antibodies accelerated ventricular enlargement to a point where a striking correlation between ventricular volume and ARIA frequency was observed.

New research confirms a key disease pathology identified through examining spinal fluid in patients with Parkinson disease.

The multicenter, multiple-ascending dose trial will feature 64 patients with ALS who will be assessed on safety and pharmacokinetic outcomes.

Evobrutinib, a highly selective BTK inhibitor, has previously demonstrated positive impacts on relapse rates and neurofilament light in patients with relapsing multiple sclerosis.

Episode 33 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 9 minutes]

On average, across all levels of physical fatigue, participants would accept a 0.32 year decrease in time to multiple sclerosis progression in exchange for a 3.57-point change in FSIQ-RMS-S score.

The neuromuscular physician at Virginia Commonwealth University talked about the promising future of gene therapy and access to resources in Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on invasive procedures for degenerative conditions and when deep brain stimulation is needed.

Sitra Tauscher-Wisniewski, MD, vice president clinical development and analytics, Novartis Gene Therapies, talked about the new data findings from a study on gene therapy Zolgensma at the 2023 MDA conference.

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]

In the phase 2 study, patients with Guillian-Barré syndrome will receive imlifidase on day 1, followed with intravenous immunoglobulin on days 3-7, with outcomes of safety and change in disability.

At the 2023 MDA’s Clinical and Scientific conference, the neurology resident at Penn Medicine talked about the challenges of delivering intrathecal therapies and the importance of planning clinical resources for patients with ALS. [WATCH TIME: 3 minutes]

Compared with children without posttraumatic headache, those who experienced migraine symptoms following concussion were nearly 3 times more likely to report reliable increases in somatic symptoms.

At 2-year follow-up, 72% of patients with drug-resistant epilepsy who underwent surgery were seizure-free, compared with 33% of patients on standard medical therapy.

Positive phase 2 data on CVN424, NETSseq platforms, and CVN417, a novel treatment for Parkinson disease, were presented at AD/PD 2023 International Conference.

The immunology fellow at Brigham and Women’s Hospital discussed the current state of care for patients with MOGAD, and whether treatment decisions differ based on timing of attacks. [WATCH TIME: 7 minutes]

After 6 months of stimulation, more than half (53%) of patients with drug-resistant epilepsy were responders to treatment with at least a 50% reduction in seizure frequency.

The co-founder and chief executive officer of MyoGene Bio talked about the advantages of gene editing over traditional gene therapy as a long term treatment for neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Incidence of narcolepsy increased 4.17- and 1.42-fold during and after the 2009 H1N1 pandemic when compared with baseline.

The research physical therapist at Nationwide Children’s Hospital talked about the role of physical therapy in the changing landscape of care with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis (MS).

New data demonstrated the potential of a new class of oral, small molecule inhibitors that target the fleeting intermediates at the core of neurodegeneration in Parkinson disease.

The phase 3 trial, pending the FDA’s approval of new finalized protocol, will be conducted across 25 to 30 sites in the US, comparing the safety of GTX-104 with oral nimodipine.

Neurology News Network for the week ending April 8, 2023. [WATCH TIME: 4 minutes]

VO659, the only clinical candidate targeting the CAG repeat expansion that causes all polyglutamine diseases, is designed to reduce mutant HTT and spare wildtype HTT.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 7, 2023.

The National Multiple Sclerosis Society’s CME program follows Project ECHO’s evidence-based telementoring model and establishes a peer-to-peer knowledge sharing network.

Increased odds of miscarriage, stillbirth, preterm birth, and maternal birth were documented in women with epilepsy. These odds were increased with greater use of antiseizure medication.